Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Metz, David C; Cadiot, Guillaume; Poitras, Pierre; Ito, Tetsuhide; Jensen, Robert T

Metz, David C; Cadiot, Guillaume; Poitras, Pierre; Ito, Tetsuhide; Jensen, Robert T.

Afiliação

Metz DC; Division of Gastroenterology, Hospital of the University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, PA, 19104, USA.
Cadiot G; Service d"Hepato-Gastroenterologie, Centre Hospitalier Universitaire de Reims, Hopital Robert Debre, F-51092, Reims, France.
Poitras P; Department of Gastroenterology, CHUM, Université de Montréal, Montreal, Canada.
Ito T; Neuroendocrine Tumor Centra, Fukuoka Sanno Hospital, International University of Health and Welfare 3-6-45 Momochihama, Sawara-Ku, Fukuoka 814-0001, Japan.
Jensen RT; Digestive Diseases Branch, NIDDK, NIH, Bethesda, Maryland, 20817, USA.

Int J Endocr Oncol ; 4(4): 167-185, 2017.

Article em En | MEDLINE | ID: mdl-29326808

Palavras-chave

MEN1; Secretin test; Zollinger-Ellison syndrome; atrophic gastritis; chromogranin A; gastric acidity testing; gastrinoma; hypergastrinemia; neuroendocrine tumor diagnosis; proton pump inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline Idioma: En Revista: Int J Endocr Oncol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google